Bold Moves

Unleash the power of our people

Lead the conversation

When some chose to politicize the development of a COVID-19 vaccine, Pfizer stood with other industry leaders and pledged to protect scientific integrity

Pfizer has a rich history in vaccine research and development. For more than 130 years, Pfizer has played a pivotal role in eliminating or nearly eliminating deadly infectious diseases like smallpox and polio. It has designed novel vaccines based on new delivery systems and technologies that have helped in preventing bacterial infections. And today, our COVID-19 vaccine developed with BioNTech SE is making history again – helping to hopefully bring an end to the worst pandemic in the past 100 years.

Pfizer’s success in pioneering vaccines is rooted in the recognition that good science demands rigor, a commitment to patient safety and a close partnership with regulators that are equally committed to scientific integrity. Together, these principles serve as a North Star that guide all efforts in the battle against disease.

The principles of scientific rigor and patient safety serve as our North Star, guiding all our efforts in the battle against disease."

In this spirit, Pfizer signed in early September a public pledge – along with a number of other vaccine researchers and developers – to protect the time-tested scientific processes and regulatory protocols that have helped guide the safe delivery of medicines and vaccines to address patients’ unmet needs. This show of solidarity complemented the five-point plan that Pfizer issued in mid-March calling for unprecedented industry collaboration in fighting COVID-19. 

The pledge reinforced Pfizer’s commitment to developing and testing potential vaccines for COVID-19 according to scientific principles, not politics. It served as a call to action for the biopharmaceutical industry – and, in fact, the entire world – to Stand with Science.

The Pfizer-BioNTech COVID-19 vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheet at

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories